BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 19123088)

  • 1. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
    Tatlicioğlu T
    Tuberk Toraks; 2008; 56(4):472-84. PubMed ID: 19123088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.
    Martina SD; Ismail MS; Vesta KS
    Ann Pharmacother; 2006 Oct; 40(10):1822-8. PubMed ID: 16985092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
    Karish SB; Gagnon JM
    Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
    Sanz MJ; Cortijo J; Morcillo EJ
    Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].
    Kreutzkamp B
    Med Monatsschr Pharm; 2010 Jul; 33(7):236-43. PubMed ID: 20687460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
    Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
    Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
    Lipworth BJ
    Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
    Xia XD; Dai YR; Xu ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan; 27(1):57-9. PubMed ID: 14989829
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
    Gross NJ; Giembycz MA; Rennard SI
    COPD; 2010 Apr; 7(2):141-53. PubMed ID: 20397815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
    Rennard SI; Schachter N; Strek M; Rickard K; Amit O
    Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective phosphodiesterase 4 inhibition. Controlling inflammation--also in patients with COPD].
    MMW Fortschr Med; 2004 Apr; 146(18):59. PubMed ID: 15366479
    [No Abstract]   [Full Text] [Related]  

  • 15. Cilomilast.
    Schachter EN
    Drugs Today (Barc); 2006 Apr; 42(4):237-47. PubMed ID: 16703120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
    Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
    Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
    Dastidar SG; Rajagopal D; Ray A
    Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDE4 inhibitors in COPD--a more selective approach to treatment.
    Vignola AM
    Respir Med; 2004 Jun; 98(6):495-503. PubMed ID: 15191033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
    Giembycz MA
    Br J Clin Pharmacol; 2006 Aug; 62(2):138-52. PubMed ID: 16842388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.